Cervical Cancer

May 25th 2023

Pembrolizumab plus chemotherapy with or without bevacizumab yields a survival benefit in PD-L1 positive patients with cervical cancer in the phase 3 KEYNOTE-826 trial.

April 27th 2023

Findings from the phase 3 OUTBACK trial show that following standard cisplatin-based chemotherapy with adjuvant chemotherapy resulted in increased toxicity among patients with cervical cancer.

April 14th 2023

Adding pembrolizumab to chemotherapy with or without bevacizumab can help patients with persistent, recurrent, or metastatic cervical cancer “live longer and better,” according to an expert from the University of Arizona College of Medicine.

April 1st 2023

A novel smoking cessation treatment for survivors of cervical cancer or cervical intraepithelial neoplasia appears to improve rates of abstinence in the short-term, but approximately matches the efficacy of standard treatment at 18 months.